Is high‐risk neuroblastoma induction chemotherapy possible without G‐CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors-Reference-Cited by-同舟云学术

Is high‐risk neuroblastoma induction chemotherapy possible without G‐CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors

Published:2020-07-30 Issue:10 Volume:67 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Whittle Sarah B.¹²^ORCID,Smith Valeria¹²,Silverstein Allison²,Parmeter Margaret¹²,Minard Charles G.³,Bernhardt M. Brooke¹²^ORCID,Zage Peter E.⁴,Venkatramani Rajkumar¹²^ORCID,Nuchtern Jed G.¹⁵⁶,Heczey Andras¹²,Russell Heidi V.¹²⁶^ORCID,Shohet Jason M.⁷^ORCID,Foster Jennifer H.¹²^ORCID

Affiliation:

1. Texas Children's Cancer and Hematology Centers Texas Children's Hospital Houston Texas

2. Department of Pediatrics Baylor College of Medicine Houston Texas

3. Institute for Clinical and Translational Research Baylor College of Medicine Houston Texas

4. Division of Hematology‐Oncology Department of Pediatrics University of California San Diego San Diego California

5. Department of Surgery Baylor College of Medicine Houston Texas

6. Center for Medical Ethics and Health Policy Baylor College of Medicine Houston Texas

7. Division of Pediatric Hematology‐Oncology Department of Pediatrics University of Massachusetts Medical School Worcester Massachusetts

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.28417

Reference27 articles.

1. Neuroblastoma: Molecular Pathogenesis and Therapy

2. Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials

3. Neuroblastoma

4. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials

5. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GM‐CSF, G‐CSF or no cytokine therapy with anti‐GD2 immunotherapy for high‐risk neuroblastoma;International Journal of Cancer;2023-12-18

2. High frequency of viridians group streptococci bacteremia in pediatric neuroblastoma high-risk patients during induction chemotherapy;Scientific Reports;2023-04-06

3. G‐CSF induces CD15 ⁺ CD14 ⁺ cells from granulocytes early in the physiological environment of pregnancy and the cancer immunosuppressive microenvironment;Clinical & Translational Immunology;2022-01